Neurodevelopmental outcome in full-term newborns with refractory neonatal seizures

Acta Paediatr. 2012 Apr;101(4):e173-8. doi: 10.1111/j.1651-2227.2011.02528.x. Epub 2011 Dec 1.

Abstract

Aim: This retrospective study describes the prognosis of full-term newborns with refractory neonatal seizures, comparing the need for treatment with two versus three or more antiepileptic drugs.

Methods: We reviewed our database (January 2002-December 2007) to include newborns with refractory neonatal seizures and abnormal electroencephalogram. Group A consisted of 17 newborns with two antiepileptic drugs. Group B consisted of 29 newborns with three or more antiepileptic drugs. Outcome was determined at 2 years of age using the Dutch Bayley Scales of Infant Development or a neurodevelopmental classification scheme.

Results: Group A and group B were comparable regarding to a variety of demographic and aetiologic factors. Thirteen newborns died before 2 years of age and one was lost to follow-up. Normal development at 2 years of age was found in 50% and 5% for group A and B, respectively. Severe neurodevelopmental delay at 2 years of age was found in 30% and 68% for group A and B, respectively.

Conclusion: The number of antiepileptic drugs probably reflects increased seizure burden and is--in that way--related to poor outcome. This may be useful information for early prediction of adverse neurological outcome in the first days of life.

Publication types

  • Comparative Study

MeSH terms

  • Anticonvulsants / therapeutic use*
  • Child Development / drug effects*
  • Child, Preschool
  • Developmental Disabilities / epidemiology*
  • Drug Therapy, Combination
  • Epilepsy, Benign Neonatal / drug therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Infant, Newborn
  • Male
  • Nervous System / growth & development*
  • Prognosis
  • Retrospective Studies
  • Seizures / drug therapy*
  • Term Birth
  • Treatment Outcome

Substances

  • Anticonvulsants